361 related articles for article (PubMed ID: 9242451)
1. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K
Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451
[TBL] [Abstract][Full Text] [Related]
2. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
3. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
[TBL] [Abstract][Full Text] [Related]
4. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
[TBL] [Abstract][Full Text] [Related]
5. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
6. Biological evaluation on different human cancer cell lines of novel colchicine analogs.
De Vincenzo R; Ferlini C; Distefano M; Gaggini C; Riva A; Bombardelli E; Morazzoni P; Danieli B; Capelli G; Mancuso S; Scambia G
Oncol Res; 1999; 11(3):145-52. PubMed ID: 10527074
[TBL] [Abstract][Full Text] [Related]
7. 9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
Zuse A; Schmidt P; Baasner S; Böhm KJ; Müller K; Gerlach M; Günther EG; Unger E; Prinz H
J Med Chem; 2006 Dec; 49(26):7816-25. PubMed ID: 17181164
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis.
Bowdon BJ; Waud WR; Wheeler GP; Hain R; Dansby L; Temple C
Cancer Res; 1987 Mar; 47(6):1621-6. PubMed ID: 3815360
[TBL] [Abstract][Full Text] [Related]
9. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
10. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
Beckers T; Reissmann T; Schmidt M; Burger AM; Fiebig HH; Vanhoefer U; Pongratz H; Hufsky H; Hockemeyer J; Frieser M; Mahboobi S
Cancer Res; 2002 Jun; 62(11):3113-9. PubMed ID: 12036922
[TBL] [Abstract][Full Text] [Related]
11. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin.
Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D
Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098
[TBL] [Abstract][Full Text] [Related]
12. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
Perchellet EM; Ladesich JB; Magill MJ; Chen Y; Hua DH; Perchellet JP
Anticancer Drugs; 1999 Jun; 10(5):489-504. PubMed ID: 10477169
[TBL] [Abstract][Full Text] [Related]
13. Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines.
Iwamoto Y; Nishio K; Fukumoto H; Yoshimatsu K; Yamakido M; Saijo N
Jpn J Cancer Res; 1998 Sep; 89(9):954-62. PubMed ID: 9818032
[TBL] [Abstract][Full Text] [Related]
14. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
Zhang LH; Wu L; Raymon HK; Chen RS; Corral L; Shirley MA; Narla RK; Gamez J; Muller GW; Stirling DI; Bartlett JB; Schafer PH; Payvandi F
Cancer Res; 2006 Jan; 66(2):951-9. PubMed ID: 16424030
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of A-105972, an antineoplastic agent.
Wu-Wong JR; Alder JD; Alder L; Burns DJ; Han EK; Credo B; Tahir SK; Dayton BD; Ewing PJ; Chiou WJ
Cancer Res; 2001 Feb; 61(4):1486-92. PubMed ID: 11245455
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activity and mechanism of action of DZ-3358, a novel pyrimidinyl pyrazole derivative.
Iwahana M; Ochi Y; Ejima A
Anticancer Res; 2000; 20(2A):785-92. PubMed ID: 10810355
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole.
Mooberry SL; Weiderhold KN; Dakshanamurthy S; Hamel E; Banner EJ; Kharlamova A; Hempel J; Gupton JT; Brown ML
Mol Pharmacol; 2007 Jul; 72(1):132-40. PubMed ID: 17456786
[TBL] [Abstract][Full Text] [Related]
18. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
19. Novel multidrug resistance reversal agents.
Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D
J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220
[TBL] [Abstract][Full Text] [Related]
20. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
